Teva officer Richard D. Francis plans $10.7M share sale

Societe Generale Private Banking (Monaco) is named as broker for the approximate November 10, 2026 sale.

Available on EDGAR 11/10/2026 - 04:17 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

TEVA Pharmaceutical Industries Limited officer Richard D. Francis reported an intended sale of 250,000 ordinary shares, with an aggregate market value of $10,742,500. The notice lists an approximate sale date of November 10, 2026, and a Rule 10b5-1 plan adoption date of June 15, 2026. The listed securities were acquired as compensation through restricted share unit vesting on February 16 and March 5, 2024, and February 19, March 4, and March 5, 2025.

Key Figures

Shares reported for sale: 250,000 ordinary shares Aggregate market value: $10,742,500 Ordinary shares outstanding: 1,164,426,972 ordinary shares +2 more

5 metrics

Shares reported for sale 250,000 ordinary shares Approximate sale date November 10, 2026

Aggregate market value $10,742,500 Securities reported for sale

Ordinary shares outstanding 1,164,426,972 ordinary shares Number outstanding listed in the securities information

Approximate sale date November 10, 2026 Date listed for the intended sale

Rule 10b5-1 plan adoption date June 15, 2026 Date listed for plan adoption

Key Terms

Rule 10b5-1, restricted share units, aggregate market value

3 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption ... If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted share units financial

"Vesting of restricted share units"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

aggregate market value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares did Richard D. Francis report for sale?

The notice lists 250,000 ordinary shares for sale, with an aggregate market value of $10,742,500.

Which broker and Rule 10b5-1 plan date are listed for the TEVA sale?

The notice names Societe Generale Private Banking (Monaco) as broker and lists June 15, 2026, as the Rule 10b5-1 plan adoption date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001673277
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Teva Pharmaceutical Industries Limited
SEC File Number	001-16174
Address of Issuer	124 Dvora HaNevi'a Street Tel Aviv ISRAEL 6944020
Phone	972-3-9148213
Name of Person for Whose Account the Securities are To Be Sold	Francis Richard D.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Societe Generale Private Banking (Monaco) 11 Avenue De Grande-Bretagne Monaco O9 98000	250000	10742500	1164426972	11/10/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	02/16/2024	Vesting of restricted share units	Teva Pharmaceutical Industries Limited			87125	02/16/2024	Compensation
Ordinary Shares	03/05/2024	Vesting of restricted share units	Teva Pharmaceutical Industries Limited			36170	03/05/2024	Compensation
Ordinary Shares	02/19/2025	Vesting of restricted share units	Teva Pharmaceutical Industries Limited			86149	02/19/2025	Compensation
Ordinary Shares	03/04/2025	Vesting of restricted share units	Teva Pharmaceutical Industries Limited			35889	03/04/2025	Compensation
Ordinary Shares	03/05/2025	Vesting of restricted share units	Teva Pharmaceutical Industries Limited			4667	03/05/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Richard D. Francis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)